Plain-English translation of NCT07136012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help prevent heart attacks and other serious heart events in people who have high levels of lipoprotein(a), a blood substance linked to heart disease risk. About 11,000 people will participate worldwide. Half will receive the new medication, and half will receive a placebo (a dummy injection), so researchers can compare how well the treatment works.
High lipoprotein(a) levels increase the risk of heart disease, but there are few treatment options available. This trial is testing whether this new medication can lower that risk and help prevent first-time heart attacks in people who have never had one before.
You likely qualify if…
You likely don't qualify if…
You will receive regular injections of either the new medication or a placebo under your skin (similar to an insulin injection). The study will track your heart health over time through visits and monitoring to see whether the treatment helps prevent heart attacks and related events. You'll be randomly assigned to receive either the medication or placebo, and neither you nor the research team will know which one you're getting until the study ends.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States